Tonix Pharmaceuticals Holding Corp. Company Profile (NASDAQ:TNXP)

About Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP)

Tonix Pharmaceuticals Holding Corp. logo

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drug Manufacturers - Major
  • Sub-Industry: N/A
  • Symbol: NASDAQ:TNXP
  • CUSIP: N/A
  • Web: www.tonixpharma.com
Capitalization:
  • Market Cap: $31.97 million
  • Outstanding Shares: 7,486,000
Average Prices:
  • 50 Day Moving Avg: $4.21
  • 200 Day Moving Avg: $1.75
  • 52 Week Range: $3.30 - $29.50
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -1.36
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: $6.47 per share
  • Price / Book: 0.66
Profitability:
  • EBIDTA: ($38,760,000.00)
  • Return on Equity: -140.86%
  • Return on Assets: -123.32%
Debt:
  • Current Ratio: 11.15%
  • Quick Ratio: 11.15%
Misc:
  • Average Volume: 1.33 million shs.
  • Beta: 2.92
  • Short Ratio: 3.68
 

Frequently Asked Questions for Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP)

What is Tonix Pharmaceuticals Holding Corp.'s stock symbol?

Tonix Pharmaceuticals Holding Corp. trades on the NASDAQ under the ticker symbol "TNXP."

How were Tonix Pharmaceuticals Holding Corp.'s earnings last quarter?

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) released its earnings results on Monday, May, 15th. The company reported ($1.27) earnings per share for the quarter, topping the consensus estimate of ($1.36) by $0.09. View Tonix Pharmaceuticals Holding Corp.'s Earnings History.

Where is Tonix Pharmaceuticals Holding Corp.'s stock going? Where will Tonix Pharmaceuticals Holding Corp.'s stock price be in 2017?

3 analysts have issued 12-month price targets for Tonix Pharmaceuticals Holding Corp.'s shares. Their predictions range from $5.00 to $8.00. On average, they anticipate Tonix Pharmaceuticals Holding Corp.'s share price to reach $6.50 in the next twelve months. View Analyst Ratings for Tonix Pharmaceuticals Holding Corp..

Are investors shorting Tonix Pharmaceuticals Holding Corp.?

Tonix Pharmaceuticals Holding Corp. saw a increase in short interest in the month of April. As of April 13th, there was short interest totalling 602,690 shares, an increase of 84.5% from the March 31st total of 326,629 shares. Based on an average daily trading volume, of 1,360,665 shares, the short-interest ratio is currently 0.4 days.

Who are some of Tonix Pharmaceuticals Holding Corp.'s key competitors?

Who owns Tonix Pharmaceuticals Holding Corp. stock?

Tonix Pharmaceuticals Holding Corp.'s stock is owned by many different of retail and institutional investors. Top institutional shareholders include OPALEYE MANAGEMENT INC. (5.52%), Vanguard Group Inc. (1.91%), Kingdon Capital Management L.L.C. (0.86%), Renaissance Technologies LLC (0.64%), Dialectic Capital Management LP (0.53%) and Citadel Advisors LLC (0.34%). Company insiders that own Tonix Pharmaceuticals Holding Corp. stock include Bradley Saenger, Bruce Daugherty, Ernest Mario, Gregory M Sullivan, John B Rhodes, Leland Gershell and Seth Lederman. View Institutional Ownership Trends for Tonix Pharmaceuticals Holding Corp..

Who sold Tonix Pharmaceuticals Holding Corp. stock? Who is selling Tonix Pharmaceuticals Holding Corp. stock?

Tonix Pharmaceuticals Holding Corp.'s stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Kingdon Capital Management L.L.C. and Vanguard Group Inc.. View Insider Buying and Selling for Tonix Pharmaceuticals Holding Corp..

Who bought Tonix Pharmaceuticals Holding Corp. stock? Who is buying Tonix Pharmaceuticals Holding Corp. stock?

Tonix Pharmaceuticals Holding Corp.'s stock was purchased by a variety of institutional investors in the last quarter, including Dialectic Capital Management LP and Citadel Advisors LLC. Company insiders that have bought Tonix Pharmaceuticals Holding Corp. stock in the last two years include Bradley Saenger, Bruce Daugherty, Ernest Mario, Gregory M Sullivan, John B Rhodes, Leland Gershell and Seth Lederman. View Insider Buying and Selling for Tonix Pharmaceuticals Holding Corp..

How do I buy Tonix Pharmaceuticals Holding Corp. stock?

Shares of Tonix Pharmaceuticals Holding Corp. can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Tonix Pharmaceuticals Holding Corp. stock cost?

One share of Tonix Pharmaceuticals Holding Corp. stock can currently be purchased for approximately $4.27.

Analyst Ratings

Consensus Ratings for Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) (?)
Ratings Breakdown: 3 Hold Ratings
Consensus Rating:Hold (Score: 2.00)
Consensus Price Target: $6.50 (52.22% upside)

Analysts' Ratings History for Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
12/20/2016Oppenheimer Holdings Inc.Reiterated RatingHoldN/AView Rating Details
9/7/2016Roth CapitalDowngradeBuy -> NeutralN/AView Rating Details
9/7/2016Cantor FitzgeraldDowngradeBuy -> HoldN/AView Rating Details
6/30/2015Janney Montgomery ScottReiterated RatingBuyN/AView Rating Details
(Data available from 5/23/2015 forward)

Earnings

Earnings History for Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP)
Earnings by Quarter for Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP)
Earnings History by Quarter for Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/15/2017Q1 2017($1.36)($1.27)ViewN/AView Earnings Details
11/10/2016Q3 2016($0.34)($0.29)ViewN/AView Earnings Details
5/9/2016Q1($0.63)($0.74)ViewN/AView Earnings Details
3/4/2016Q4($0.66)($0.71)ViewN/AView Earnings Details
8/10/2015Q215($0.65)($0.73)ViewN/AView Earnings Details
5/11/2015Q115($0.54)($0.71)ViewN/AView Earnings Details
3/3/2015Q414($0.81)($0.83)ViewN/AView Earnings Details
11/10/2014Q314($0.69)($0.71)ViewN/AView Earnings Details
8/8/2014Q214($0.53)($0.61)ViewN/AView Earnings Details
5/13/2014Q114($0.35)($0.59)ViewN/AView Earnings Details
3/31/2014($0.46)($0.74)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP)
2017 EPS Consensus Estimate: ($2.79)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.83)($0.83)($0.83)
Q2 20171($0.69)($0.69)($0.69)
Q3 20171($0.65)($0.65)($0.65)
Q4 20171($0.62)($0.62)($0.62)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP)
Insider Ownership Percentage: 10.20%
Institutional Ownership Percentage: 10.19%
Insider Trades by Quarter for Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP)
Institutional Ownership by Quarter for Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP)
Insider Trades by Quarter for Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/23/2016Ernest MarioDirectorBuy120,000$0.41$49,200.00View SEC Filing  
9/13/2016Ernest MarioDirectorBuy100,000$0.79$79,000.00View SEC Filing  
6/22/2016Seth LedermanCEOBuy20,000$2.08$41,600.00View SEC Filing  
6/21/2016Bradley SaengerCFOBuy2,000$2.00$4,000.00View SEC Filing  
6/21/2016Bruce DaughertyInsiderBuy100,000$2.00$200,000.00View SEC Filing  
6/21/2016John B RhodesDirectorBuy25,000$2.00$50,000.00View SEC Filing  
6/3/2016Gregory M SullivanInsiderBuy20,000$2.50$50,000.00View SEC Filing  
5/12/2016Ernest MarioDirectorBuy31,042$2.30$71,396.60View SEC Filing  
5/11/2016Ernest MarioDirectorBuy8,210$2.24$18,390.40View SEC Filing  
3/23/2016Seth LedermanCEOBuy8,000$2.44$19,520.00View SEC Filing  
3/16/2016Ernest MarioDirectorBuy75,000$2.29$171,750.00View SEC Filing  
9/30/2015Gregory M SullivanInsiderBuy5,000$5.18$25,900.00View SEC Filing  
9/28/2015Gregory M SullivanInsiderBuy4,694$5.95$27,929.30View SEC Filing  
9/25/2015Seth LedermanCEOBuy6,000$6.50$39,000.00View SEC Filing  
8/26/2015Ernest MarioDirectorBuy10,000$6.05$60,500.00View SEC Filing  
8/25/2015Ernest MarioDirectorBuy1,468$6.40$9,395.20View SEC Filing  
8/24/2015Ernest MarioDirectorBuy2,532$6.20$15,698.40View SEC Filing  
8/20/2015Ernest MarioDirectorBuy6,000$6.64$39,840.00View SEC Filing  
8/17/2015Ernest MarioDirectorBuy15,000$6.93$103,950.00View SEC Filing  
7/17/2015John B RhodesDirectorBuy6,000$7.50$45,000.00View SEC Filing  
7/17/2015Leland GershellCFOBuy1,000$7.50$7,500.00View SEC Filing  
6/11/2015Gregory M SullivanInsiderBuy4,500$8.38$37,710.00View SEC Filing  
3/17/2015Seth LedermanCEOBuy2,000$7.02$14,040.00View SEC Filing  
3/13/2015Seth LedermanCEOBuy2,000$7.24$14,480.00View SEC Filing  
3/11/2015Seth LedermanCEOBuy2,000$6.95$13,900.00View SEC Filing  
3/10/2015Charles E Iv MatherDirectorBuy1,000$6.80$6,800.00View SEC Filing  
3/9/2015Seth LedermanCEOBuy2,000$6.48$12,960.00View SEC Filing  
3/6/2015Ernest MarioDirectorBuy4,000$6.57$26,280.00View SEC Filing  
3/5/2015Seth LedermanCEOBuy2,000$6.27$12,540.00View SEC Filing  
2/9/2015Ernest MarioDirectorBuy30,000$5.85$175,500.00View SEC Filing  
2/9/2015Leland GershellCFOBuy5,000$5.85$29,250.00View SEC Filing  
9/27/2013Charles E Iv MatherDirectorBuy1,000$3.65$3,650.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP)
Latest Headlines for Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP)
Source:
DateHeadline
streetinsider.com logoTonix Pharma (TNXP) Reports Analyses of Potential Moderators of ... - StreetInsider.com
www.streetinsider.com - May 23 at 8:47 AM
streetinsider.com logoTonix Pharma (TNXP) Reports Analyses of Potential Moderators of Treatment Response to TNX-102 SL, in Phase 2 AtEase Study in Military-Related PTSD
www.streetinsider.com - May 22 at 7:15 PM
finance.yahoo.com logoTonix Pharmaceuticals Presented Analyses of Potential Moderators of Treatment Response to U.S. FDA-Designated Breakthrough Therapy for PTSD, TNX-102 SL, in Phase 2 AtEase Study in Military-Related PTSD
finance.yahoo.com - May 22 at 7:15 PM
finance.yahoo.com logoToday's Research Reports on Stocks to Watch: Tonix Pharmaceuticals and Calithera Biosciences
finance.yahoo.com - May 22 at 8:33 AM
americanbankingnews.com logoZacks Investment Research Analysts Decrease Earnings Estimates for Tonix Pharmaceuticals Holding Corp. (TNXP)
www.americanbankingnews.com - May 22 at 7:18 AM
seekingalpha.com logoTonix Pharma up 7% premarket on institutional stakes
seekingalpha.com - May 19 at 6:18 PM
finance.yahoo.com logoTNXP: Interim Analysis for HONOR Study Expected in 1H18
finance.yahoo.com - May 19 at 1:15 PM
americanbankingnews.com logoTonix Pharmaceuticals Holding Corp. (TNXP) Announces Quarterly Earnings Results
www.americanbankingnews.com - May 16 at 4:44 PM
reuters.com logoBRIEF-Tonix Pharmaceuticals reports Q1 loss per share $1.27
www.reuters.com - May 15 at 8:55 AM
finance.yahoo.com logoTonix Pharmaceuticals Reports First Quarter 2017 Financial Results and Provides Programs Update
finance.yahoo.com - May 15 at 8:54 AM
finance.yahoo.com logoTonix reports 1Q loss
finance.yahoo.com - May 15 at 8:54 AM
americanbankingnews.com logoTonix Pharmaceuticals Holding Corp. (TNXP) Set to Announce Quarterly Earnings on Monday
www.americanbankingnews.com - May 6 at 7:14 AM
americanbankingnews.com logoTonix Pharmaceuticals Holding Corp. (TNXP) Expected to Post Earnings of -$1.10 Per Share
www.americanbankingnews.com - May 3 at 12:02 PM
nasdaq.com logoTNX-102 SL is an FDA-Designated Breakthrough Therapy for PTSD in Phase 3 Development
www.nasdaq.com - May 2 at 6:17 PM
americanbankingnews.com logoTonix Pharmaceuticals Holding Corp. (TNXP) Earning Favorable News Coverage, Analysis Finds
www.americanbankingnews.com - May 2 at 1:30 PM
americanbankingnews.com logoTonix Pharmaceuticals Holding Corp. (TNXP) Sees Significant Growth in Short Interest
www.americanbankingnews.com - May 2 at 11:36 AM
bizjournals.com logoDrug Makers Stocks Under Scanner -- Novartis, TherapeuticsMD, Tonix Pharma, and Retrophin
www.bizjournals.com - May 2 at 8:52 AM
finance.yahoo.com logoTonix Pharmaceuticals Announces Issuance of U.S. Patent for TNX-102 SL Composition and Formulation: Designed for Transmucosal Absorption and Bedtime Daily Use
finance.yahoo.com - May 2 at 8:52 AM
americanbankingnews.com logoResearch Analysts Issue Forecasts for Tonix Pharmaceuticals Holding Corp.'s Q1 2017 Earnings (TNXP)
www.americanbankingnews.com - April 24 at 7:02 AM
finance.yahoo.com logoTNXP: Potential for Only One Phase 3 Trial Needed for TNX-102 SL in PTSD
finance.yahoo.com - April 21 at 8:03 PM
americanbankingnews.com logoTonix Pharmaceuticals Holding Corp. (TNXP) Given Media Sentiment Score of 0.12
www.americanbankingnews.com - April 21 at 6:12 PM
finance.yahoo.com logoTonix Pharmaceuticals Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Programs Update
finance.yahoo.com - April 17 at 8:34 AM
marketbeat.com logoTonix reports 4Q loss
marketbeat.com - April 17 at 7:54 AM
finance.yahoo.com logoTonix Pharmaceuticals Announces Full Exercise and Closing of Underwriters’ Over-Allotment Option
finance.yahoo.com - April 13 at 8:08 PM
streetinsider.com logoTonix Pharma (TNXP) Receives Official Minutes from FDA on Initial Cross-Disciplinary Breakthrough Meeting on TNX-102
www.streetinsider.com - April 11 at 9:11 AM
finance.yahoo.com logoTonix Pharmaceuticals Reports Results from U.S. FDA Initial Cross-Disciplinary Breakthrough Meeting on TNX-102 SL for Posttraumatic Stress Disorder
finance.yahoo.com - April 11 at 9:11 AM
finance.yahoo.com logoTonix Pipeline Review Closer to the Commercialization of a New PTSD Treatment
finance.yahoo.com - April 7 at 1:03 PM
finance.yahoo.com logoTonix Pharmaceuticals Completes $8 Million Public Offering of Common Stock
finance.yahoo.com - April 7 at 1:03 PM
us.rd.yahoo.com logoTonix Pharmaceuticals Regains Compliance with NASDAQ Minimum Bid Price Requirement
us.rd.yahoo.com - April 3 at 8:05 PM
us.rd.yahoo.com logoIs This The Start of a Turnaround for DryShips and Tonix, or will Management Burn Investors Again
us.rd.yahoo.com - April 3 at 8:05 PM
seekingalpha.com logoTonix Pharmaceuticals: Good And Bad News - Seeking Alpha
seekingalpha.com - April 1 at 6:41 AM
us.rd.yahoo.com logoTonix Pharmaceuticals Prices Public Offering of 1,800,000 Shares of Common Stock
us.rd.yahoo.com - March 31 at 3:32 AM
biz.yahoo.com logoTONIX PHARMACEUTICALS HOLDING CORP. Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Fin
biz.yahoo.com - March 31 at 3:32 AM
rttnews.com logoTonix Pharmaceuticals Holding (TNXP) Has Surged To Nearly A 6-Month High
www.rttnews.com - March 30 at 5:52 AM
globenewswire.com logoTonix Pharmaceuticals to Present FDA Breakthrough Therapy-Designated PTSD Program at The MicroCap Conference - GlobeNewswire (press release)
globenewswire.com - March 29 at 7:19 AM
finance.yahoo.com logoTonix Pharmaceuticals to Present FDA Breakthrough Therapy-Designated PTSD Program at The MicroCap Conference
finance.yahoo.com - March 29 at 7:19 AM
americanbankingnews.com logo Tonix Pharmaceuticals Holding Corp. (TNXP) Receives Average Rating of "" from Analysts
www.americanbankingnews.com - March 28 at 11:46 AM
streetinsider.com logoTonix Pharma (TNXP) Announces 1st Participant in Military-Related PTSD Phase 3 Trial of TNX-102 SL
www.streetinsider.com - March 28 at 8:50 AM
us.rd.yahoo.com logoTonix Pharmaceuticals Enrolls First Participant in Military-Related PTSD Phase 3 Trial of FDA Breakthrough Therapy-Designated TNX-102 SL
us.rd.yahoo.com - March 28 at 8:50 AM
seekingalpha.com logoTonix Pharmaceuticals Holding (TNXP) Presents At Oppenheimer 27th Annual Healthcare Conference - Slideshow
seekingalpha.com - March 23 at 1:14 AM
finance.yahoo.com logoTONIX PHARMACEUTICALS HOLDING CORP. Financials
finance.yahoo.com - March 21 at 8:02 PM
biz.yahoo.com logoSplits Calendar: Tonix Pharma splits before market open today (1:10 ratio)
biz.yahoo.com - March 18 at 2:13 AM
us.rd.yahoo.com logoTonix Pharmaceuticals Announces 1-for-10 Reverse Stock Split
us.rd.yahoo.com - March 17 at 1:43 AM
biz.yahoo.com logoTONIX PHARMACEUTICALS HOLDING CORP. Files SEC form 8-K, Material Modification to Rights of Security Holders, Amendmen
biz.yahoo.com - March 17 at 1:43 AM
streetinsider.com logoTonix Pharma (TNXP) Announces Composition & Manufacturing US Patent for TNX-102 SL - StreetInsider.com
www.streetinsider.com - March 16 at 3:06 AM
finance.yahoo.com logoTonix Pharmaceuticals to Present Breakthrough Therapy Designated-PTSD Program at Oppenheimer’s 27th Annual Healthcare Conference
finance.yahoo.com - March 15 at 8:07 AM
reuters.com logoBRIEF-Tonix Pharma receives notice of allowance for new U.S. Patent
www.reuters.com - March 14 at 8:59 AM
finance.yahoo.com logoTonix Pharmaceuticals Receives Notice of Allowance for New U.S. Patent Covering Composition and Manufacture of TNX-102 SL
finance.yahoo.com - March 14 at 8:59 AM
finance.yahoo.com logo7:02 am Tonix Pharma announces that the U.S. Patent and Trademark Office has issued a Notice of Allowance for U.S. Patent Application covering composition and manufacture of tnx-102 sl
finance.yahoo.com - March 14 at 8:59 AM
biz.yahoo.com logoTONIX PHARMACEUTICALS HOLDING CORP. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
biz.yahoo.com - March 14 at 8:59 AM

Social

Chart

Tonix Pharmaceuticals Holding Corp. (TNXP) Chart for Tuesday, May, 23, 2017

This page was last updated on 5/23/2017 by MarketBeat.com Staff